TEE
ACRS icon

Tibra Equities Europe’s Aclaris Therapeutics ACRS Stock Holding History

Tibra Equities Europe’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-110,600
Closed -$662K – 232
2019
Q1 		$662K Buy
+110,600
New +$733K 0.07% 230

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Tibra Equities Europe's ACRS Position: Q2 2019 in Review

Tibra Equities Europe sold out of Aclaris Therapeutics (ACRS) in Q2 2019, closing a stake of 110,600 shares — an estimated $662K sold.

Tibra Equities Europe first reported a position in ACRS in Q1 2019 and held it in 1 quarter. The position peaked at $662K in Q1 2019. 84 funds tracked by Wall St. Rank hold ACRS as of Q2 2019.

  • Tibra Equities Europe reported no remaining Aclaris Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 110,600 Aclaris Therapeutics shares in Q2 2019, an estimated $662K.
  • Tibra Equities Europe first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Aclaris Therapeutics position peaked at $662K in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.